8-K: Quantumzyme Rebrands to Quantum Genesis AI Corp.

Quantumzyme Corp. announced its Board and majority shareholders approved a name change to Quantum Genesis AI Corp., pending regulatory filings.

Summary

• The Board of Directors and the holder of a majority of the voting power of Quantumzyme Corp. approved an amendment to the Company's Articles of Incorporation on November 30, 2025.
• The Company's name will change from Quantumzyme Corp. to Quantum Genesis AI Corp.
• The Certificate of Amendment has not yet been filed with the Nevada Secretary of State.
• The Name Change will become effective following the completion of the Company's Schedule 14C information statement process and the expiration of the applicable 20-day waiting period required under federal securities laws.
• An Issuer Company-Related Action Notification Form has been filed with FINRA to reflect the Name Change and apply for a new stock symbol.
• The Name Change will not affect the rights of shareholders, authorized capital, issued and outstanding shares, CUSIP number, or par value.
• A new ticker symbol will be assigned by FINRA upon completion of its review.

Sentiment

Score: 6

Explanation: The name change to 'Quantum Genesis AI Corp.' suggests a strategic pivot towards artificial intelligence, which could be viewed positively by the market, though no immediate financial impact or operational changes are detailed. The procedural delays are standard for such corporate actions.

Positives

• The new name, 'Quantum Genesis AI Corp.', suggests a strategic pivot or increased focus on artificial intelligence, which could attract new investor interest in a high-growth sector.
• The name change does not negatively impact shareholder rights, authorized capital, issued and outstanding shares, CUSIP number, or par value.

Future Outlook

The company intends to update shareholders and the markets upon FINRA's approval and the deemed effectiveness of the name change and new stock symbol. The name change itself suggests a future strategic focus on artificial intelligence.

Management Comments

• We will endeavor to update our shareholders, and the markets generally, upon approval and deemed effectiveness by FINRA.

Industry Context

The inclusion of 'AI' in the new company name aligns with a broader industry trend of companies emphasizing their involvement in artificial intelligence to capitalize on investor enthusiasm and perceived growth opportunities within the technology sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Rights are unaffected; potential for increased investor interest due to the strategic alignment with the artificial intelligence sector.
• Regulatory Bodies: Requires compliance with SEC (Schedule 14C, waiting period) and FINRA (new stock symbol) procedures.

Next Steps

• File the Certificate of Amendment with the Nevada Secretary of State.
• Complete the Schedule 14C information statement process.
• Await the expiration of the applicable 20-day waiting period under federal securities laws.
• Await FINRA's approval and assignment of a new stock symbol.
• Update shareholders and the markets upon effectiveness of the name change and new stock symbol.

Key Dates

Recommendation

The name change to Quantum Genesis AI Corp. signals a potential strategic shift towards the high-growth artificial intelligence sector. While this could attract new investor interest and improve market perception, the filing provides no immediate operational or financial details to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further disclosures regarding the company's actual AI initiatives and business strategy.

Keywords

Quantumzyme, Quantum Genesis AI, Name Change, Corporate Rebranding, AI, Artificial Intelligence, SEC Filing, 8-K, Corporate Action